§ Claim under review · Mixed
"Japan has developed a universal artificial blood that works with all blood types and has an extended lifespan compared to donated blood." (Post: "Japanese researchers have developed an artificial blood that works for every blood type, removing the need to match a patient's type before a transfusion. It's also been engineered to last far longer than donated blood... The research is still progressing through clinical trials.")
Verdict
Mostly accurate
Confidence
HighSummary
This one is largely true, with important caveats. Researchers at Nara Medical University in Japan have created an artificial oxygen carrier made by extracting hemoglobin from expired donated blood and sealing it inside tiny fat capsules. Because these capsules carry no blood type markers, they can in principle be given to anyone without cross-matching, and published lab data support storage of about two years at room temperature compared with roughly three to six weeks for donated red cells. However, calling it "artificial blood" oversells it: it only replaces the oxygen-carrying job of red blood cells and contains no platelets or clotting factors. It is also not a finished product. The human studies so far tested safety in a small number of healthy volunteers, a larger safety trial is still running, and the team is aiming for regulatory approval around 2030. Effectiveness in actual bleeding patients has not yet been demonstrated.
The readings
key figures from the evidenceHbV storage shelf life at room temperature
refrigerated donated red blood cell shelf life
HbV plasma half-life at 100 mL dose
Why this verdict
Evidence
The underlying technology is real and well documented. The product, haemoglobin vesicles (NMU-HbVs, Nara Medical University Haemoglobin Vesicles), contains purified human haemoglobin encapsulated within liposomes and has been developed as a potential alternative to blood transfusions in emergency situations.
It is manufactured by extracting haemoglobin from expired donor blood and encasing it in a lipid shell; these vesicles transport oxygen without carrying blood type markers, making them universally compatible.
On the "all blood types" element, the developing institution states directly that because the product reuses haemoglobin from unused or discarded red cells, it carries no infection risk, and because it is not a red blood cell it has no blood type, so it can be used in patients of any blood type and can be stockpiled long term .
On storage, a peer-reviewed stability study reports that deoxygenation of Hb-V prevents autoxidation of haemoglobin and can extend its shelf life to 2 years at room temperature , with 98.1% of intact lipids remaining after 4 years and 90.4% after 7.2 years at 4 °C . Sakai's own review confirms deoxygenated HbV can be stored for over two years at room temperature using a saturated phospholipid, DPPC, to avoid lipid peroxidation, combined with PEGylation . For comparison, refrigerated red blood cells in additive solutions have a shelf life of 42 days , and in Japan the period has historically been even shorter: the preservation period of donated red blood cells is limited to 3 weeks in Japan .
On trial stage, the first-in-human study was small. The phase I trial was an open-label, single intravenous injection, dose-escalation study across three cohorts of four participants each, receiving 10, 50 and 100 mL; infusion reactions such as burning sensation, flushing and headache were observed in cohorts 1 and 3.
Low-grade fever occurred in some participants, all adverse events were tolerated and resolved spontaneously without medication, laboratory deviations recovered to normal ranges, no clinically significant vital sign changes were observed, and HbV circulated with a plasma half-life of approximately 8 hours at the 100 mL dose.
A phase Ib dose-escalation study with a maximum infusion dose of 400 mL is currently underway to further confirm safety and tolerability.
Findings
✓ What's accurate 5
- A Japanese artificial oxygen carrier (haemoglobin vesicles) genuinely exists and is in human clinical trials led by Hiromi Sakai at Nara Medical University.
- It genuinely lacks blood-group antigens, so cross-matching by ABO/Rh type is not required.
- The extended storage claim is supported by peer-reviewed stability data: roughly 2 years at room temperature, with lipid integrity largely preserved for years under refrigeration, against 3 to 6 weeks for donated red cells.
- The post correctly states the research is still in clinical trials, which is accurate.
- Early safety signals were modest: transient fever, rash, flushing and headache, all self-resolving.
≈ What's misleading 5
- **Omitted qualifier (material):** "Artificial blood" implies a whole-blood substitute. HbV replaces only the oxygen-carrying function of red cells. It contains no platelets, no clotting factors, no plasma proteins and no white cells. It cannot treat coagulopathic bleeding on its own.
- **Temporal overreach / "has developed":** The phrase suggests a finished, available product. It is an investigational agent in phase Ib safety testing in healthy volunteers, with approval targeted around 2030 at the earliest. Many prior haemoglobin-based oxygen carriers worldwide failed at later stages.
- **Exaggeration of evidence strength:** "Early results point toward a real shift" overstates what has been shown. The published human data measure safety, tolerability and pharmacokinetics in 12 healthy men, not clinical benefit in bleeding patients. No human efficacy endpoint has been reported.
- **Short circulation time omitted:** a plasma half-life of about 8 hours at 100 mL means HbV is a bridging oxygen carrier, not a replacement for transfusion over days.
- **"Faster transfusions, less waste":** plausible operational benefits, but these are projected advantages, not demonstrated outcomes.
? What's uncertain 4
- Results of the ongoing phase Ib trial have not been published in peer-reviewed form at the time of this review. Only the protocol and media reports of dosing are available.
- The "about six years refrigerated" figure comes from institutional press statements reported in Japanese media, not from a peer-reviewed storage endpoint I located. The published stability paper supports multi-year lipid integrity at 4 °C but is not the same as a regulatory shelf-life designation.
- Whether HbV will show efficacy in haemorrhagic shock patients is untested in humans.
- Final dose, cost, manufacturing scale and regulatory outcome are all unknown.
Sources
2 of 7 linked to records**BMJ Open, phase Ib study protocol (Jan 2026)**
**Blood Advances, first-in-human phase 1 trial (Oct 2022)**
**Springer book chapter, "Phase I Clinical Trial of Hemoglobin Vesicles" (2026)**
**Kure, Ochiai & Sakai, storage stability study (PubMed 38804272)**
**Frontiers in Medical Technology (Sakai, 2022), review of HbV development**
**Nara Medical University press conference coverage (Nara TV, Jiji, Mynavi, July 2024)**
**Newsweek / Cybernews / TBS News (2025)**